Browse Articles
Discover research articles across all indexed journals
A Chain Entanglement Gelled SnO₂ Electron Transport Layer for Enhanced Perovskite Solar Cell Performance and Effective Lead Capture
AbstractSnO₂ is a widely used electron transport layer (ETL) material in perovskite solar cells (PSCs), and its design and optimization are essential for achieving efficient and stable PSCs. In this study, the in situ formation of a chain entanglement gel polymer electrolyte is reported in an aqueous phase, integrated with SnO₂ as the ETL. Based on the self‐polymerization of 3‐[[2‐(methacryloyloxy)ethyl]dimethylammonium]propane‐1‐sulfonic acid (DAES) in an aqueous environment, combining the catalytic effect of LiCl (as a Lewis acid) with the salting‐out effect, and the introduction of polyvinylpyrrolidone (PVP) as the other polymer chain, a chain entanglement gelled SnO2 (G‐SnO2) structure is successfully constructed with a wide range of functions. The PDEAS‐PVP chain entanglement gel achieves passivation and Pb2⁺ capture through chemical chelation mechanisms is explored. The results demonstrated that the all‐in‐air prepared PSC based on G‐SnO2 exhibited an excellent power conversion efficiency (PCE) of 24.77% and retained 83.3% of their initial efficiency after 2100 h of air exposure. Additionally, the PDEAS‐PVP exposes more C═O and S═O active sites, significantly enhanced the lead absorption capability of the PSCs.
Annual incidence of colorectal cancer among patients with average risk in the United States between 2017 and 2023.
83 Background: Colorectal cancer (CRC) is the second most common cause of cancer-related mortality and third most common cancer in the United States. In 2021, 141,902 new cases of CRC were reported. With recent increases in early onset of CRC incidence, a shift in patterns amongst various demographics has been observed. Together with an estimated 60% increase in burden of CRC globally, it is important to continuously assess the nationwide incidence rates and monitor the changing patterns. In this study, we examined the annual incidence rates of CRC in average risk adults using a large national claims database and report patterns of incidence based on various demographic characteristics. Methods: CRC diagnoses were retrospectively identified from a large national claims database, which covers over 165 million lives and is representative of the U.S. population, for each calendar year during the study period from 2017 to 2023. Individuals aged 45 to 75 years, with an average risk of CRC before each index calendar year were included in the study. Individuals were required to be continuously enrolled in the same health plan for at least 1 year prior to and 1 year following the index year. Annual CRC incidence rates per 100,000 people were calculated for each year from 2017 to 2023 within various subgroups based on baseline demographics. Results: Overall, annual CRC incidences remained consistent during the study period with 186.86 (95% CI, 184.87-188.86) cases in 2017 and 183.40 (95% CI, 181.32-185.5) cases in 2023 per 100,000. Among younger adults aged 45-49 years, the annual CRC incidence increased by 66% from 2017 (92.04 cases/100,000) to 2023 (153.12 cases/100,000). Conversely, annual CRC incidence decreased by 25% between 2017 (328.52 cases/100,000) and 2023 (244.93/100,000) in older adults aged 65-75 years. Over the study period, CRC incidence in men was higher than women with an overall rate ratio (RR) of 1.206 (95% CI, 1.122-1.297). African American adults had higher CRC incidence than White Americans with an overall rate ratio (RR) of 1.216 (95% CI, 1.152-1.283). Conclusions: Based on this large study of national claims data, CRC incidence rates remained relatively stable in the total population among average-risk patients from 2017 to 2023. The continuing increase in recommended CRC screening utilization showed a decreased incidence rate in the older population, while observing increased incidences among younger patients.
Disparities in outcomes of pancreatic cancer hospitalizations: A ten-year trend study.
683 Background: Pancreatic cancer is the third leading cause of cancer mortality in the United States with 51,750 estimated deaths from Pancreatic cancer in 2024. Demographic variations have been reported with Pancreatic cancer. Our aim was to identify trends in demographic-specific disparities in inpatient pancreatic cancer outcomes. Methods: This is a retrospective longitudinal trends study using the Nationwide Inpatient Sample (NIS) database (2010-2019). We identified hospitalizations with pancreatic cancer using ICD-9 and ICD-10 codes. We highlight disparities in mortality outcomes stratified by age, gender and race. Results: There were 992,550 hospitalizations of pancreatic cancer patients between 2010 and 2019. Over the period, the mean age at hospitalization was similar at 68 years (P = 0.006). A majority of the admissions were elderly patients (≥65 years) identifying as males and Caucasians (P < 0.01). Most patients had Medicare and were in large and urban teaching hospitals (P < 0.001). Over the decade, there was an overall decline in inpatient mortality, from 8.2% in 2010 to 7.1% in 2019 (P trend = 0.004). Amidst the age subgroups, only the elderly patient group experienced a significant decline in mortality rate (8.8% to 7.3%; P trend = 0.004). The young adult population (<45 years) had a trend towards increasing mortality rate, but it was not significant (P trend= 0.139). On gender subgroup analysis, only males had a significant decline in mortality rate (P trend= 0.003). On racial subgroup analysis, only Caucasians had a significant decline in mortality trend (P trend= 0.004) during the study period. Conclusions: There was an overall improvement in the mortality outcome of pancreatic cancer hospitalizations. On sub-group analysis, significant decline in mortality over the decade were seen only in elderly, male and Caucasian patient groups. Targeted research is needed in understanding the root causes of these disparities in pancreatic cancer outcomes and develop effective intervention to bridge this gap. Trends in mortality outcomes of pancreatic cancer hospitalizations by demographic subgroups. Mortality rate, % 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 P- Trend value Overall 8.21 7.94 7.85 7.70 7.73 7.68 7.46 7.87 7.47 7.14 0.004 Young (<45 years) 4.45 5.55 5.23 6.08 6.27 5.32 3.63 6.84 6.95 6.35 0.14 Middle-aged (45- 64 years) 7.55 7.24 7.74 7.32 7.03 6.99 7.62 6.80 6.74 6.91 0.06 Elderly (>65 years) 8.81 8.44 8.04 8.00 8.22 8.19 7.54 8.48 7.87 7.29 0.004 Females 7.72 7.32 7.23 7.15 6.99 7.31 6.72 7.38 7.01 6.87 0.08 Males 8.67 8.57 8.44 8.22 8.44 8.04 8.13 8.32 7.90 7.38 0.003 Whites 7.94 7.49 7.48 7.39 7.81 7.29 6.81 7.39 7.19 6.80 0.004 Blacks 9.87 9.40 9.38 9.15 8.35 8.13 9.40 9.01 8.55 8.41 0.07 Hispanics 7.10 8.99 8.02 6.85 6.66 8.80 7.54 7.43 7.10 6.14 0.05
Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.
558 Background: Proteinuria presents a challenging complication during systemic therapy for hepatocellular carcinoma (HCC). This study aims to identify risk factors for proteinuria in patients with HCC treated with atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first-line systemic treatment. Methods: A retrospective analysis was conducted on 622 consecutive patients with unresectable HCC who received Atezo/Bev or LEN as first-line systemic treatment between October 2013 and October 2022. Cumulative incidence of proteinuria was estimated using Kaplan–Meier curves and compared using log-rank tests. Risk factors for proteinuria were identified using Cox proportional-hazard models, along with propensity score-matched and subgroup analyses. Results: Among 367 patients treated with Atezo/Bev and 255 with LEN, the cumulative incidence of proteinuria at 12 months was 27.5%. In the multivariable analysis, Atezo/Bev treatment (HR, 1.57; 95% CI, 1.03–2.42), diabetes (HR, 1.64; 95% CI, 1.03–2.61), Child–Pugh class B (HR, 3.43; 95% CI, 1.34–8.78), macrovascular invasion (MVI; HR, 1.58; 95% CI, 1.04–2.38), and an estimated glomerular filtration rate ≤60 mL/min/1.73 m 2 (HR, 3.21; 95% CI, 1.84–5.62) were identified as risk factors for proteinuria. A higher risk of proteinuria in Atezo/Bev patients compared with LEN was consistently observed in the PS-matched cohort, particularly pronounced in subgroups with MVI (HR, 2.84; 95% CI, 1.23–6.54) compared with those without MVI (HR, 1.31; 95% CI, 0.69–2.47). Conclusions: Patients treated with Atezo/Bev as first-line systemic treatmentfor HCC exhibited a higher risk of proteinuria compared with those with LEN, particularly when accompanied by MVI.
Ferroelectric Optical Memristors Enabled by Non‐Volatile Electro‐Optic Effect
Abstract Memristors enable non‐volatile memory and neuromorphic computing. Optical memristors are the fundamental element for programmable photonic integrated circuits due to their high‐bandwidth computing, low crosstalk, and minimal power consumption. Here, an optical memristor enabled by a non‐volatile electro‐optic (EO) effect, where refractive index modulation under zero field is realized by deliberate control of domain alignment in the ferroelectric material Pb(Mg 1/3 Nb 2/3 )O 3 ‐PbTiO 3 (PMN‐PT) is proposed. The non‐volatile EO memristor is designed exclusively for the modulation of the optical phase without degrading the optical transparency, and it allows the support for deterministic and repeated non‐volatile multilevel EO states. A non‐volatile tunable waveplate composed of the optical memrisor for free‐space optics, which allows for deterministic multilevel, and non‐volatile phase shifts from 0 to π /2 is presented. The state switching rate of the memristor is less than 100 ms, with a switching energy consumption of 234 nJ, and the states can be retained for up to 12 h without requiring static power consumption. These results demonstrate a novel approach to fully realizing non‐volatile optical memristors, where only optical phase modulation is involved, providing unprecedented opportunities for the development of new ferroelectric memristors.
Spatial transcriptomics and lethality-associated stromal remodeling of colorectal cancer.
227 Background: Colorectal cancer (CRC) is surgically resectable and eminently screenable yet remains a lethal entity with high affinity to metastasise synchronously and metachronously. It has been proposed that cellular and extracellular components of the microenvironment contribute to metastatic potential. Dissociative profiling techniques such as bulk transcriptomic and single-cell RNA sequencing have contributed insight but limited therapeutic progress. Spatial transcriptomic (ST) assessment allows molecular profiling of tissue while preserving tissue architecture. Here we employ ST approaches to interrogate tumor compartments of primary resectable and matched synchronous CRC demonstrating stromal signatures with distinct collagen expression associated with outcome. Methods: 25 patients with primary resectable CRC and 4 patients with matched primary CRC and liver metastasis (CRLM) underwent single-cell spatial transcriptomics using the Nanostring CosMx Spatial Molecular Imager (SMI, 1000plex gene panel) (Discovery cohort). 71681 epithelial and 88806 stromal cells with intact spatial resolution were analysed. The spatial single-cell signatures were reconstituted in 89 patients using the Nanostring GeoMx Digital Spatial Profiler (Validation cohort). 3 GeoMx compartments were analysed: Epithelial (PanCK+); Stroma (aSMA+); Immune (PanCK-aSMA-). Results: CosMx demonstrated 2 distinct collagen signatures: COL1A1,COL1A2,COL3A1 associated with normal fibroblasts; COL9A2 associated with cancer-related stroma and lethal subtypes of epithelial cell. In the GeoMx validation cohort, 42 patients expressed the COL1A1 signature in the aSMA compartment and 47 did not (5 year recurrence free survival: 0.88 vs 0.49, p < 0.005) with different morphological patterns of each distinct aSMA group. In patients with favourable prognosis, chemokine high epithelial subtypes expressed CXCL5 and recruited COL9A2-, IL6+ neutrophils to the surrounding microenvironment. In contrast, epithelial cells in patients with poor prognosis expressed CXCL8 and recruited COL9A2+ neutrophils which were frequently in contact with SPP1+ macrophages. Conclusions: We have used ST approaches to interrogate cellular compartments of CRC demonstrating stromal subtypes that impact outcome. These insights could be used in the clinical setting to quantify COL9A2 expression in aSMA+ cells to prognosticate patients. Targeting of tumor collagen has been proposed to augment existing anti-cancer therapies and this work has demonstrated COL9A2 as a potential target in need of further investigation.
Systematic literature review (SLR) of prognostic factors (PFs) in locally advanced rectal cancer (LARC) and mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer (RC).
303 Background: Innovative immunotherapies arebeing developed to improve clinical outcomes in patients (pts) withdMMR/MSI-H LARC who respond poorly to the current standard of care. A comprehensive overview of PFs in dMMR/MSI-H LARC may provide insight into the natural history of this disease to inform clinical study design and pt risk stratification. Methods: Systematic searches of bibliographic databases (EMBASE, MEDLINE, Cochrane; 2013–2023) and congress websites (2021–2023) were conducted to identify PFs for tumor response and survival outcomes in adult pts with LARC (SLR1) and dMMR/MSI-H RC (SLR2). Given the expected high volume of evidence, SLR1 was limited to large observational studies (≥1000 pts) and clinical trials (≥100 pts); SLR2 had no such limits. Results: 95 of 2307 publications met the inclusion criteria for SLR1. Of the PFs reported in ≥20 studies, older age, more lymph node involvement or fewer nodes assessed, higher T-stage or larger tumor size, higher histologic grade, and more comorbidities were most frequently significantly associated with poorer patient prognosis (Table). 3 of 289 publications met the inclusion criteria for SLR2. Neoadjuvant chemoradiation therapy (CRT) compared to chemotherapy (CT) was associated with statistically significant worse disease-free survival (DFS) and distant metastasis-free survival (DMFS), while T- or N-stage, age, and sex did not significantly impact these outcomes. Low vs middle tumor localization was also associated with worse DMFS. Stage III and IV disease were associated with worse RC-specific survival, while surgical procedure (segmental vs extended) showed no difference in overall survival (OS). The addition of neoadjuvant CRT or adjuvant CRT/CT to surgery alone had no impact on OS but was associated with worse DFS. Conclusions: Evidence regarding PFs in dMMR/MSI-H RC is scarce and may limit its interpretability, highlighting the need for further research that may be informed by the PFs identified from SLR1. The results from these SLRs may be helpful for optimizing patient management and treatment decision making, and to further contextualize RC clinical trials. PFs reported in ≥20 studies with ≥75% of studies reporting significant results in pts with LARC. PF Studies reporting PF (n) Studies reporting significant* impact of PF on prognosis (%) Poorer prognosis group Top 2 most frequently reported outcomes Age 59 81.4 Older OS, DFS Lymph node involvement/assessment 55 78.2 Yes or higher N stage OS, DFS T-stage or tumor size 53 79.2 Higher or larger OS, DFS Histologic grade 37 75.7 Higher OS, pathological complete response (pCR) Comorbidities 23 87.0 More OS, pCR *p-value <0.05 was considered significant as reported in the identified studies.
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
TPS313 Background: Currently, pembrolizumab is one of the front-line therapies for patients with MSI-H CRC. However, approximately 40% of patients who received pembrolizumab experienced disease progression early in the course of disease (KEYNOTE 177). Therefore, there is still an unmet need to enhance the efficacy of checkpoint inhibitors in MSI-H CRC. MSI-H CRC has a higher level of expression of VEGF in blood compared to patients compared to its MSS counterpart (Hansen et al. Colorectal Dis. 2011). Consistently, exploratory analysis of CALBG-80405 and PARADIGM trial showed that patients with MSI-H CRC were more likely to benefit from anti-VEGF therapy than anti-EGFR therapy regardless of the side of the tumor. NSABP C-08 also suggested that anti-VEGF therapy may have biological activity even in as adjuvant therapy for patients with MSI-H colon cancer. Regorafenib is a potent VEGF inhibitor, with preclinical evidence showing its immune modulatory effect in the tumor microenvironment. In this trial, we hypothesize that adding low-dose regorafenib to pembrolizumab may induce synergistic activity beyond their independent clinical efficacy and create deep and durable responses for patients with MSI-H CRC. Methods: In the lead arm of this prospective randomized study, 22 patients will be enrolled through Hoosier Cancer Research Network (HCRN-GI23-643). Patients with treatment naïve MSI-H CRC will be enrolled in this front-line trial. One cycle of pembrolizumab and up to 3 cycles of chemotherapy prior to determination of MMR-D/MSI-H is allowed. Patients will receive regorafenib 60 mg daily in combination with pembrolizumab 200mg IV in cycle 1, followed by regorafenib 90mg in subsequent cycles to improve treatment tolerance. The primary outcome that will be measured is ORR, defined as the percentage of partial or complete response to the treatment within 12 months. ORR will be measured using RECIST 1.1. criteria. A formal one-sided hypothesis test will be conducted for futility, assuming that we will reject the null hypothesis of a target ORR only if we have strong evidence. In this study, we assume a null hypothesis that ORR is 0.60, which would reflect significant clinical improvement over the current standard of ORR = 0.43 from KEYNOTE 177. The alternative hypothesis is that ORR is less than 0.60. For the lead-in phase of the study, the emphasis is on controlling Type I error to be small, approximately 0.05. The test statistic will be the number of ORRs in the 22 patients, which we assume to follow a binomial distribution. Clinical trial information: NCT06006923 .
Prediction of relapse-free survival in stage III gastric cancer patients treated with postoperative adjuvant chemotherapy: Random survival forest analysis from the START-2 trial.
446 Background: The START-2 trial demonstrated that docetaxel plus S-1 (DS) was superior to S-1 alone (S-1) in terms of recurrence-free survival (RFS) and overall survival (OS) as the adjuvant chemotherapy for stage III gastric cancer (GC) patients (pts) (J Clin Oncol 2019, Gastric Cancer 2022). We conducted the START-2 AR study as a retrospective analysis using data from the START-2 trial to develop a prognostic model for stage III GC pts treated with postoperative chemotherapy. Methods: Among 912 pts in the START-2 trial, 599 pts signed the consent form to participate in the START-2 AR study. There were 542 pts (265 pts in DS group and 277 pts in S-1 group) without missing values of prognostic candidates. Pts were randomly divided into a training set and a validation set with a ratio of 7:3. Prognostic model for RFS was developed using random survival forest (RSF) with the training set. The RSF model was applied to the validation set to assess its performance, evaluated using Harrell's C-index. We calculated tertiles of risk scores from the RSF model to divide the training set into low-, middle-, and high-risk subgroups. These cut-off values were used to classify the validation set. A Cox proportional hazard model was applied to compare the prognosis among the risk groups. Results: There were no statistically significant differences in patient characteristicsbetween the 599 pts in the START-2 AR study and the 912 pts in the STRAT-2 trial. RFS was comparable between the two groups. The RSF model for the training set (n = 380) yielded a C-index of 0.873, identifying the number of metastatic lymph nodes, serum albumin, CEA, tumor diameter, the primary tumor location, platelet count, age as prognostic factors in order of importance. In the validation set (n = 162), the C-index was 0.648. Both the low-risk group (n = 35) (hazard ratio [HR]: 0.34, 95% confidence interval [CI]: 0.17 – 0.68, p < 0.01) and the middle-risk group (n = 74) (HR: 0.55, 95% CI: 0.33 – 0.89, p = 0.02) in the validation set had significantly better RFS compared to the high-risk group (n = 53). Among the 76 pts in the low-risk group treated with DS, 44 were categorized into the low-risk group when assuming they had been treated with S-1 alone. The analysis of 599 pts after multiple imputation yielded results consistent with those from the complete data. Conclusions: We developed the RSF-based predictive model for stage III GC pts, which demonstrated good performance. The number of metastatic lymph modes was identified as the most important prognostic factor. Risk stratification based on this model effectively differentiated prognostic outcomes. Future external validation of the model is required. Clinical trial information: UMIN000011438.
Investigating the clinical and molecular characteristics of class II and III BRAF mutations and their response to anti-EGFR therapy in MSS CRC: A comprehensive analysis.
274 Background: BRAF mutations (mts) are a heterogeneous group of molecular alterations seen in colorectal cancer (CRC). Class I BRAF mts (V600) are known to be associated with aggressive biology to CRC, but the knowledge of clinical characteristics of class II and III BRAF mts is limited. In this large cohort analysis, we evaluated the clinical and molecular features of class II and III BRAF mts and performed comparative analyses for their impact on survival outcomes. Methods: A total of 24402 MSS CRC samples were profiled by NGS (592-gene, NextSeq; WES, WTS NovaSeq) (Caris Life Sciences, Phoenix, AZ). BRAF mts were detected by NGS and classified using published literature (1). MAPK pathway activity score (MPAS) was calculated using RNA expression data. Real-world overall survival (OS) was obtained from insurance claims and calculated from tissue collection to last contact, while post-treatment survival from first treatment to last contact. KM estimates were calculated for defined patient cohorts. Significance was determined as P<0.05. Results: A total of 1270, 134, and 327 patients with class I, II, and III BRAF mts were identified. BRAF mts overall and class I BRAF mts were significantly less common among younger pts (age<50) compared to patients ≥ 50 (4.7% vs. 7.4 %; P< 0.001 and 3.2% vs. 5.7%, respectively, P<0.001). Class I BRAF mts were enriched with consensus molecular subtype 1 (CMS1) (class I, II, and III: 46% vs. 14% vs. 18% respectively) while class II and III mts had more CMS2 subtype compared to class I (2%, 30% and 29%, p<0.05). Higher MPAS scores were noted among patients with class I BRAF mts than those with class II and III mts (1.73 versus 0.38 vs 0.79). Class I BRAF mts and KRAS mts were nearly mutually exclusive (0.5%), while KRAS mts were relatively common among class II and III mts (12.8% and 27.4%, respectively). Median OS for patients with wild-type BRAF , class I, II, and III BRAF mts were significantly different (29.8, 17.3, 21.8, and 24.6 months, respectively, p<0.01). Similar OS was seen among patients who did not receive anti-EGFR therapy (28.3, 15.2, 20.7- and 21.9 months P<0.001). Patients with class III mts had significantly better OS compared to patients with class I mts (HR=1.28 CI: 1.09-1.48 p=0.002), and while no significant difference was noted for patients with class II vs class I mts, numerically more favorable outcomes were noted (mOS 21.8 vs 17.3 months P=0.133). Among treated with anti-EGFR, patients with class II and III BRAF mts had numerically better post-anti-EGFR survival compared to class I mts; however, this was not statistically significant (21.2 vs 14.2 vs. 10.4 respectively P=0.3). Conclusions: Class II and III BRAF mts represent a distinct biological subgroup of MSS CRC with distinct prognoses. Class II and III BRAF mts are associated with improved survival outcomes compared to patients with class I mts. 1. Sahin et al. JCO OP 2021.
Predictive methylation signature for gemcitabine sensitivity in pancreatic ductal adenocarcinoma: A pathway to personalized treatment.
768 Background: Gemcitabine (Gem) is a key drug used in chemotherapy regimens for treating pancreatic ductal adenocarcinoma (PDA). Identifying a biomarker to predict patient response to Gem could be crucial in personalizing treatment selection between Gemcitabine and fluorouracil (5-FU)-based therapies, thereby improving patient outcomes. We hypothesize that DNA methylation changes in genes linked to Gem resistance may serve as surrogates for the expression of corresponding proteins, thereby predicting treatment outcomes in patients with PDA receiving this therapy. Methods: We curated a 93-gene panel through a literature review spanning from January 1970 to April 2024. The proteins encoded by these genes have demonstrated either preclinical evidence (from cell line or mouse models) or clinical evidence (from tissue-based studies) of affecting the response to Gem in PDA. We evaluated the prognostic significance of methylation at specific CpG (cytosine-phosphate-guanine) sites within these genes using data from The Cancer Genome Atlas (TCGA) database, focusing on patients who had received Gem (106 /184 patients). We utilized elastic net multivariate analysis to analyze survival and created Kaplan-Meier plots based on our gene panel to estimate overall survival (OS). We compared RNA and gene expression levels for the clinically significant gene signatures between normal (NT) and PDA tissues using TNMplot.com, a web-based tool developed from data in the Gene Expression Omnibus of the National Center for Biotechnology Information (NCBI-GEO), TCGA, Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and The Genotype-Tissue Expression (GTEx) repositories. This tool employs Mann-Whitney or Kruskal-Wallis tests to determine statistical significance. Results: We identified an 8-CpG site methylation signature across eight genes, distinguishing a high-risk subgroup within the Gem-treated cohort in the TCGA database. Patients exhibiting methylation at specific CpG sites in this signature experienced significantly worse OS, with median survival times of 20.35 months compared to 49.38 months (p=0.0068). Additionally, the RNA expression (fold change: 2.11, p=2.12e-55) and gene expression (fold change: 1.42, p=3.14e-18) of these genes were markedly higher in PDA tissues compared to normal tissues. Notably, the candidate genes in our signature do not overlap with those used to classify PDA into classical versus basal subtypes. In an ongoing study, we are also investigating methylation changes of these candidate genes in the blood (cell-free DNA) of PDA patients. Conclusions: We present a signature that can predict Gem sensitivity or resistance in patients with PDA. This signature serves as a critical first step toward personalizing treatment strategies.
Programmable Electromagnetic Wave Absorption via Tailored Metal Single Atom‐Support Interactions
Abstract Metal single atoms (SA)‐support interactions inherently exhibit significant electrochemical activity, demonstrating potential in energy catalysis. However, leveraging these interactions to modulate electronic properties and extend application fields is a formidable challenge, demanding in‐depth understanding and quantitative control of atomic‐scale interactions. Herein, in situ, off‐axis electron holography technique is utilized to directly visualize the interactions between SAs and the graphene surface. These interactions facilitate the formation of dispersed nanoscale regions with high charge density and are highly sensitive to external electromagnetic (EM) fields, resulting in controllable dynamic relaxation processes for charge accumulation and restoration. This leads to customized dielectric relaxation, which is difficult to achieve with current band engineering methods. Moreover, these electronic behaviors are insensitive to elevated temperatures, having characteristics distinct from those of typical metallic or semiconducting materials. Based on these results, programmable EM wave absorption properties are achieved by developing a library of SA‐graphene materials and precisely controlling SA‐support interactions to tailor their responses to EM waves in terms of frequency and intensity. This advancement addresses the customized anti‐EM interference requirements of electronic components, greatly enhancing the development of integrated circuits and micro‐nano chips. Future efforts will concentrate on manipulating atomic interactions in SA‐support, potentially revolutionizing nanoelectronics and optoelectronics.
Efficacy and safety of trifluridine/tipiracil and bevacizumab (FTD/TPI+BEV) in patients with metastatic colorectal cancer (mCRC) in real-world practice.
204 Background: In Sunlight trial, the combination of FTD/TPI + BEV showed a significant improvement in Overall Survival (OS) and Progression-Free Survival (PFS), along with better Objective Response Rate (ORR) and Disease Control Rate (DCR), compared to FTD/TPI alone, in patients with mCRC progressing after two chemotherapy regimens. The BeTAS trial aimed to evaluate the effectiveness and safety of the FTD/TPI + BEV combination in real-world practice. Methods: This was a retrospective, observational, multicenter study of mCRC patients treated with FTD/TPI+BEV in routine clinical practice across 11 Spanish university hospitals. It included patients with mCRC who were refractory or intolerant to standard therapies. Results: A total of 208 patients treated with FTD/TPI+BEV between July 2019 and December 2023 were included. The median age was 69 years (range 33 to 88 years), with 59.8% being male. 15.3% had an ECOG performance status of 2, 55.9% had RAS mutations, 30.3% had three or more metastatic sites, and 81.2% had liver metastases. Additionally, 19.8% had a time from diagnosis of first metastasis of less than 18 months, and 55.3% were categorized in Tabernero's Unfavorable Prognostic Subgroup. Most patients (81.3%) received FTD/TPI+BEV as third-line therapy, with 90.5% having previously received anti-VEGF therapy. The median number of treatment cycles was 4 (range 1 to 31 cycles). The ORR was 4.6%, and the DCR was 50%. The median PFS was 4.9 months (95% CI, 4.0-5.7 months), and the median OS was 11.1 months (95% CI, 9.5-12.8 months). The most common grade 3-4 toxicities included neutropenia (41.8%), asthenia (7.2%), and hepatic toxicity (5.5%). No treatment-related deaths were reported. Conclusions: Our series confirms the efficacy and safety of FTD/TPI + BEV in routine clinical practice, even in a population with poor prognosis and an extensive history of previous treatments.
Selective internal radiation therapy with yttrium-90 resin microspheres followed by lenvatinib plus PD-1 inhibitor for large or huge advanced-stage hepatocellular carcinoma: A retrospective cohort study from China.
581 Background: Yttrium-90 resin microspheres have been introduced into China in recent years, but the efficacy or safety on Chinese patients are rarely reported. This study aimed to evaluate the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres followed by lenvatinib and PD-1 inhibitor in Chinese patients with large (5.1–10.0 cm in diameter) or huge (>10.0 cm) advanced-stage hepatocellular carcinoma (HCC). Methods: Data of large or huge Barcelona Clinic Liver Cancer stage C HCC patients treated with SIRT followed by lenvatinib plus PD-1 inhibitor from November 2022 to October 2023 were prospectively collected and retrospectively analyzed. Key endpoints included overall survival (OS), progression-free survival (PFS), complete response rate (CRR), objective response rate (ORR), disease control rate (DCR) based on modified Response Evaluation Criteria in Solid Tumors, and adverse events (AEs) graded based on Common Terminology Criteria for Adverse Events v5.0. Risk factors affecting PFS were analyzed using univariate and multivariate Cox regression models. Results: A total of 30 patients (27 males, 3 females; mean age 54 ± 11 years) were included. The mean longest diameter of the tumor was 9.6 ± 4.2 cm (range: 5.2–17.6 cm). Nineteen (63.3%) patients had more than three intrahepatic lesions, 15 (50.0%) had vascular invasion, and 13 (43.3%) had extrahepatic metastasis. Sixteen (53.3%) patients had undergone prior anticancer therapies. Two patients received two SIRT procedures, and the rest had one. Lenvatinib and PD-1 inhibitor treatment was initiated 3–7 days after the initial SIRT procedure. CRR was 20.0%, ORR was 73.3%, and DCR was 90.0%. Median PFS was 8.0 months (95% CI, 5.6–10.4), and median OS was not reached. OS rates at 6, 12, and 18 months were 93%, 74%, and 74%, respectively. Univariate and multivariate analysis indicated that baseline alpha-fetoprotein levels, baseline eosinophil count, and neutrophil-to-lymphocyte ratio at 1 month after SIRT were independent risk factors for PFS. AEs of any grade occurred in 86.7% of patients, with grade 3 AEs in 23.3%, and no grade 4/5 AEs were recorded. Conclusions: SIRT followed by lenvatinib and PD-1 inhibitor demonstrates promising efficacy and a favorable safety profile in Chinese patients with large or huge advanced-stage HCC.
Cohort-level patient-derived organoid assays and prediction of clinical trial outcomes in PDAC.
785 Background: Clinical trials are one of the major barriers in contemporary drug development. Improving the number of therapeutic solutions for patients whilst limiting the financial burden of healthcare systems will require dramatically improving clinical trial success rates. Functional assays based on patient-derived organoids (PDO) are a promising new tool for derisking clinical development of new therapies, but their use has been limited due to small cohort sizes and the absence of systematic validation studies. Methods: We have assembled a collection of 70 demographically relevant PDAC PDOs. Each PDO was screened with a 22-drug panel including standard of care, chemotherapies and targeted therapies. Using a best-in-class patient response prediction model we generate cohort scale estimations of overall response rates (ORR) and progression-free survival (PFS). The estimations are compared with data from published clinical trials to determine the validity of the approach. Results: The PDOs exhibit representative treatment histories in terms of number of lines of treatment (mean = 1.60) and treatment types (prior treatment types: folfirinox = 68.6%, gemcitabine = 50%). All the organoids’ mutational profile, past patient treatments and subsequent responses to future lines were analyzed and compared to the distributions observed in the clinic. The cohort-level drug efficacy on our PDO collection matches retrospective clinical trial ORRs reported in the literature. Furthermore, our preclinical assay predicts the relative performance of drugs in different clinical trial arms. Conclusions: We report that large-scale PDO-based assays predict clinical ORR and PFS with best-in-class accuracy. This work shows that well-characterized PDO collections can be used to improve the success rates of clinical studies for new potential treatments in PDAC.
Enhancing Photovoltaically Preferred Orientation in Wide‐Bandgap Perovskite for Efficient All‐Perovskite Tandem Solar Cells
Abstract Wide‐bandgap perovskite solar cells (WBG PSCs) have promising applications in tandem devices yet suffer from low open‐circuit voltages ( V OC s) and less stability. To address these issues, the study introduces multifunctional nicotinamide derivatives into WBG PSCs, leveraging the regulation on photovoltaically preferential orientation and optoelectronic properties via diverse functional groups, e.g., carbonyl, amino. Isonicotinamide (IA) molecule emerges as the most effective agent, enhancing crystallization kinetics and defect passivation due to its unique planar spatial configuration. Incorporating IA into WBG perovskites improves the (100) preferred crystal orientation, reduces trap density, and enables well‐matched energy band alignment. High‐performance 1.77 eV WBG PSCs are achieved with a champion power conversion efficiency of 19.34% and a V OC of 1.342 V, leading to the fabrication of the best‐performing all‐perovskite tandem solar cell with a PCE of 28.53% (certified 28.27%) and excellent operational stability, maintaining over 90% of the initial efficiency under 1 sun illumination for 600 h.
What is the optimal treatment strategy of salvage line treatment after progression on anti-epidermal growth factor receptor monoclonal antibody in patients with tissue <i>RAS/BRAF</i> wild-type metastatic colorectal cancer?
138 Background: Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) and anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) re-challenge are treatment options for tissue RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) in salvage line, although the optimal treatment sequence of salvage line remains unclear. Methods: RAS/BRAF WT mCRC patients refractory to anti-EGFR mAb were retrospectively enrolled at a single cancer institute from November 2017 to April 2024. We compared responses, progression-free survival (PFS), and overall survival (OS) between Group A (anti-EGFR mAb re-challenge given first) and B (FTD/TPI plus BEV given first). We compared responses between Group C (treated with anti-EGFR mAb re-challenge at any line) and D (treated with FTD/TPI plus BEV at any line). We explored the clinical factors related to the treatment efficacy using multivariate analysis. Results: A total of 89 patients (median age, 63 years) were included. The cohort included 74 patients with a primary lesion in the left-sided colon, while 15 patients had a primary lesion in the right-sided colon. The response rate (RR) was 3.4%. The disease control rate (DCR) was 52.8%. The median PFS (mPFS) and OS (mOS) were 3.5 months (95% confidence interval [CI], 2.8-4.2) and 12.8 months (95% CI, 8.8-15.7) respectively. Two of 18 patients (11.1%) in Group A and 1 of 71 patients (1.4%) in Group B achieved partial response (PR). The RR of Group C was significantly higher than Group D (9.6% vs 1.2%; p = 0.031). Both PFS and OS showed no significant difference between Group A and B (mPFS: 3.3 vs 3.9 months; hazard ratio [HR], 1.08; 95% CI, 0.63-1.84; p = 0.79) (mOS: 12.8 vs 15.0 months; HR, 0.90; 95% CI, 0.49-1.65; p = 0.72). Multivariate analysis identified that primary tumor resection was associated with PFS (HR, 0.44; 95% CI, 0.25–0.80; p = 0.0068) and primary tumor resection (HR, 0.34; 95% CI, 0.18–0.65; p = 0.0010) and serum CA19-9 level (HR, 1.75; 95% CI, 1.02-3.00; p = 0.043) were associated with OS. Conclusions: No significant survival difference was observed between patients administered anti-EGFR mAb re-challenge first and those administered FTD/TPI plus BEV first, whereas the RR of anti-EGFR mAb re-challenge is significantly higher than that of FTD/TPI plus BEV.
Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859.
376 Background: In the phase 3 KEYNOTE-859 study (NCT03675737; N = 1579), patients (pts) with locally advanced or metastatic HER2-negative G/GEJ cancer treated with first-line pembrolizumab (pembro) plus chemotherapy (chemo) had a significant and clinically meaningful improvement in OS with manageable toxicity vs placebo (pbo) plus chemo while maintaining HRQoL in the intention-to-treat and prespecified PD-L1 combined positive score (CPS) populations. We report data from an analysis of quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST). Methods: Q-TWiST is a measure of survival weighted by health states utility values. The analysis categorized survival time into 3 health states: time with grade ≥3 AEs (toxicity [TOX]) and time without symptoms or toxicities (TWiST)—both before disease progression or death—and relapse (REL), defined as time from disease progression to death. Q-TWiST was calculated as the restricted mean survival time (RMST) spent in each state, with a weighted health state utility for that state. Average utility weights were derived based on pooled EQ-5D-5L scores using the US mapping algorithm and standardized base case utility weights. Relative gains in Q-TWiST of ≥10% and ≥15% were “clinically important” and “clearly clinically important,” respectively, as reported in the literature. Treatment difference 95% CIs were generated using the nonparametric bootstrapping method. Data are reported for all randomly assigned pts and pts with PD-L1 CPS ≥1 and CPS ≥10 tumors. The data cutoff date was August 22, 2023. Results: At the maximum follow-up of 56 mo for pembro plus chemo vs pbo plus chemo, RMST was 5.16 vs 2.86 mo for TOX, 7.77 vs 5.87 mo for TWiST, and 6.85 vs 7.12 mo for REL. Between-treatment differences are shown in the table. The difference in restricted mean Q-TWiST and relative gain favored pembro plus chemo. Conclusions: A clearly clinically important Q-TWiST gain was observed for pembro plus chemo vs pbo plus chemo in all pts with advanced HER2-negative G/GEJ cancer and pts with PD-L1 CPS ≥1 and CPS ≥10 tumors. Clinical trial information: NCT03675737 . All ptsN = 1579 PD-L1 CPS ≥1n = 1235 PD-L1 CPS ≥10n = 553 RMST in TOX, mo (95% CI) 2.30(1.28 to 3.44) 2.65(1.46 to 3.99) 4.28(2.08 to 6.41) RMST in TWiST, mo (95% CI) 1.90(−0.02 to 3.79) 2.28(0.07 to 4.49) 3.72(0.43 to 7.19) RMST in REL, mo (95% CI) −0.28(−2.43 to 2.01) −0.22(−2.88 to 2.39) −0.45(−4.52 to 3.71) Restricted meanQ-TWiST, mo (95% CI) a 3.31(2.10 to 4.59) 3.98(2.60 to 5.43) 6.45(4.26 to 8.74) Relative Q-TWiST gain, % (95% CI) a 20.90(12.49 to 30.56) 25.34(16.04 to 36.26) 38.05(23.21 to 56.59) Restricted meanQ-TWiST, mo (95% CI) b 2.91(1.58 to 4.14) 3.50(2.02 to 4.88) 5.63(3.31 to 7.99) Relative Q-TWiST gain, % (95% CI) b 18.38(9.78 to 27.46) 22.27(12.65 to 32.52) 33.19(18.76 to 49.97) a Based on US mapping algorithm. b Based on standardized base case utility weights.
Real world data and biomarker analysis of the efficacy and safety of PD-1 inhibitor combined with chemotherapy in first-line treatment of advanced gastric cancer.
342 Background: With the publication of several clinical research results, the efficacy of ICI combined with chemotherapy has gradually been recognized in HER-2 negative advanced GC field. We analyzed the efficacy of 1st-line PD-1 inhibitor combined with chemotherapy in advanced GC patients using real-world data and conducted exploratory analysis. We aim to identify factors that can predict treatment efficacy, and provide a basis for clinical practice. Methods: We prospectively collected data from GC patients between November 2020 and April 2024. The clinical staging was stage IV. All patients were HER2 negative and pMMR. All patients received SOX regimen chemotherapy combined with PD-1 inhibitor. Blood samples were collected for exploratory analysis. Results: A total of 190 GC patients with histological diagnosis of adenocarcinoma were included from November 1, 2020 to April 1, 2024. As of June 1, 2024, the median follow-up time was 11.75 (95% CI 10.65-13.00) months. Among them, 174 had measurable lesions. 94 patients achieved PR, and 55 patients achieved SD. The ORR and DCR were 61.9% (95% CI 48.8-73.4%) and 96.8% (95% CI 89.0-99.6%), respectively. The survival analysis results indicated that the mPFS and mOS were 9 (95% CI 7.9-14.2) and 27 (95% CI 20- not reached) months. We conducted risk factor analysis on patients , age, gender, CPS, HER2 expression, EGFR expression and EBER status. Age, gender, CPS, EBER status and EGFR expression are not risk factors affecting survival. Specifically, the expression level of HER2 was significantly correlated with therapeutic efficacy. The results indicated that the HER2 expression level was significantly correlated with ORR. In terms of survival analysis, the PFS of treated patients with HER2 ‘2+’ was significantly longer than that of treated patients with HER2 ‘1+’, and there was a trend of prolonged OS, but the statistical difference was not reached. We collected baseline blood samples from 62 patients and performed ctDNA testing. In terms of PFS, the patients with SNV in SMARCA4 and RASA1 was significantly shorter than that of wild-type patients with SMARCA4 ( p = 0.02) and RASA1 ( p = 0.043). The patients with CNV in EXT1 was significantly shorter than those with wild-type in EXT1 ( p = 0.00046). In terms of OS, patients with SNV in BRCA2, TP53, and STK11 had significantly shorter OS than those with wild-type BRCA2 ( p = 0.033), TP53 ( p = 0.048), and STK11 ( p = 0.0083). The patients with CNV in MYC and EXT1 had shorter OS than those with wild-type MYC ( p < 0.0001) and EXT1 ( p < 0.0001) patients. Conclusions: Real-world data showed that 1st-line treatment with PD-1 inhibitor combined with SOX had shown good efficacy in advanced GC patients. The HER2 expression level in HER2 negative GC may become a direction for further exploration. The EXT1 mutation can serve as a potential predictor, and further investigation is warranted. Clinical trial information: NCT06034964 .
Leech‐Inspired Amphibious Soft Robot Driven by High‐Voltage Triboelectricity
AbstractLeech locomotion, characterized by alternating sucker attachment and body contraction provides high adaptability and stability on complex terrains. Herein, a leech‐inspired triboelectric soft robot is proposed for the first time, capable of amphibious movement, climbing, and load‐carrying crawling. A high‐performance triboelectric bionic robot system is developed to drive and control electro‐responsive soft robots. Its core components include: i) a leech‐inspired soft robot (LSR) made from segmented dielectric elastomer muscles. ii) The triboelectric sucker produces anisotropic frictional forces. iii) The multi‐channel high‐voltage output triboelectric nanogenerator (HDC‐TENG) effectively drives the LSR. iv) The high‐voltage triboelectric control unit adapted for the HDC‐TENG enables flexible LSR control. Using the scalable structure of the dielectric elastomer muscles enables the LSR to achieve a maximum crawling speed of 0.39 body lengths per minute on land (45 mm min−1) and 0.22 body lengths per minute in liquid (30.5 mm min−1). It can also carry a payload of 11.55 grams on acrylic while crawling. This research provides a sustainable and promising new solution for self‐powered high‐voltage energy sources suitable for electro‐responsive soft robots.